As we’ve seen in past quarters, the unit benefited from its Acuvue contact lens products, as well as electrophysiology devices for cardiovascular applications and endocutters in J&J’s advanced surgery business. The acquisitions of Abbott Medical Optics and privately held specialists Megadyne Medical Products and Torax Medical helped boost the unit’s prospects for the quarter. Consumer sales lost some momentum, seeing growth slow to just 1%. Without acquisitions, the unit would have seen its top line fall, and U.S. sales dramatically outperformed J&J’s international revenue. go nowTylenol and other over-the-counter products did fairly well, but oral care, baby care, and wound care products didn’t pull their weight during the quarter. Most importantly, pharmaceutical sales lagged the rest of the company’s performance, with sales gains of just 0.8%. Drug sales internationally grew while domestic revenue dropped, and J&J pointed to the success of multiple myeloma treatment Darzalex and blood-cancer drug Imbruvica as key contributors to its overall performance. Can Johnson & Johnson grow faster?
For the original version including any supplementary images or video, visit https://www.fool.com/investing/2017/04/18/johnson-johnson-posts-sluggish-sales-boosts-guidan.aspx